Skip to main content
main-content

Rheumatology

Rheumatology

21-11-2019 | Rheumatology | News | Article

axSpA management needs to look beyond disease activity and function

To improve the quality of life of patients with ankylosing spondylitis, research suggests that fatigue, poor sleep, and mental health need to be addressed in addition to managing disease activity and function.

21-11-2019 | Rheumatology | News | Article

RA comorbidities signal a need to screen

US researchers have identified a number of chronic conditions associated with rheumatoid arthritis, including some that may predispose to RA development and others that may arise as a result of RA.

20-11-2019 | Rheumatology | News | Article

Insufficient diversity in RA clinical trial populations

A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.

19-11-2019 | Rheumatology | News | Article

Omega-3 supplements may benefit in RA patients

Taking omega-3 is associated with a reduction in measures of rheumatoid arthritis disease activity, suggests real-world data.

18-11-2019 | Rheumatology | News | Article

No benefit of add-on fenebrutinib for patients with SLE

Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.

15-11-2019 | Rheumatology | News | Article

Further investigation of telitacicept may be warranted for SLE

Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.

14-11-2019 | Rheumatology | News | Article

Sustained benefits of ixekizumab over adalimumab in PsA

Follow-up results from the SPIRIT-H2H trial indicate that ixekizumab continues to improve joint and skin symptoms relative to adalimumab after 1 year of treatment among patients with psoriatic arthritis.

13-11-2019 | Rheumatology | News | Article

Apremilast reduces oral ulcer burden in Behçet’s syndrome

The small molecule phosphodiesterase 4 inhibitor apremilast reduces the number of oral ulcers and improves quality of life to a greater degree than placebo in people with Behçet’s syndrome, results of the phase III RELIEF study show.

13-11-2019 | Rheumatology | News | Article

TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE

Anifrolumab has shown clinical efficacy in systemic lupus erythematosus, based on BICLA response as the primary outcome, TULIP-2 results show.

13-11-2019 | Rheumatology | News | Article

Secukinumab may represent a treatment option for nonradiographic axSpA

The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.

13-11-2019 | Rheumatology | News | Article

Tofacitinib shows efficacy in polyarticular juvenile idiopathic arthritis

Tofacitinib is effective for reducing the risk for disease flare in patients with polyarticular juvenile idiopathic arthritis, results of a randomized phase III study show.

13-11-2019 | Rheumatology | News | Article

IL-17A inhibition may be beneficial for nonradiographic axSpA

The interleukin-17A inhibitor ixekizumab improves the signs and symptoms of nonradiographic axial spondyloarthritis relative to placebo, indicate findings from the phase III COAST-X trial.

13-11-2019 | Rheumatology | News | Article

Pooled filgotinib data confirm good tolerability in patients with RA

A pooled analysis of data from the FINCH 1–3 studies has shown that 24 weeks of filgotinib treatment is well tolerated by a broad group of patients with rheumatoid arthritis, with an adverse event profile similar to that of its comparators.

12-11-2019 | Rheumatology | News | Article

Upadacitinib demonstrates potential for ankylosing spondylitis

Findings from the phase II/III SELECT-AXIS 1 trial suggest that treatment with upadacitinib may improve disease activity, function, and axial inflammation among biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to NSAIDs.

12-11-2019 | Rheumatology | News | Article

Continuing ixekizumab superior to withdrawal for stable psoriatic arthritis patients

Patients with psoriatic arthritis who have achieved minimal disease activity on ixekizumab do better if they continue on the drug rather than stopping treatment, show findings from the SPIRIT-P3 study.

12-11-2019 | Rheumatology | News | Article

Methotrexate disappoints in hand osteoarthritis trial

Methotrexate does not improve pain or physical function among people with symptomatic erosive hand osteoarthritis, indicate results from the placebo-controlled ADEM trial.

12-11-2019 | Rheumatology | News | Article

Bimekizumab benefits for ankylosing spondylitis extend beyond 12 weeks

Bimekizumab shows sustained benefit in the treatment of patients with ankylosing spondylitis, 48-week data show.

12-11-2019 | Rheumatology | News | Article

Study challenges safety concerns over live vaccine use in rheumatic disease patients

Trial findings reported at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA, refute concerns that patients with rheumatic diseases taking TNF inhibitors should not be given the live varicella virus vaccine.

11-11-2019 | Rheumatology | News | Article

Naproxen recommended over low-dose colchicine for gout flares

Naproxen and low-dose colchicine are similarly effective in the reduction of pain associated with gout flares, but patients receiving colchicine tend to experience more side-effects, show results from the multicenter, open-label CONTACT trial.

11-11-2019 | Rheumatology | News | Article

Certolizumab pegol shows dual role for axSpA and acute anterior uveitis

Certolizumab pegol significantly reduces the risk for acute anterior uveitis flare in patients with axial spondyloarthritis, show 48-week interim results from the C-VIEW trial.